P53 control of bone remodeling

Journal of Cellular Biochemistry

Volumn 111, Issue 3, 2010, Pages 529-534

  Liu, Huijuan ^a   Li, Baojie ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

Bone Remodeling; Osteoblast Differentiation; P53

Indexed keywords

ABELSON KINASE; ATM PROTEIN; BONE MORPHOGENETIC PROTEIN; PROTEIN MDM2; PROTEIN P53; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BLAST TRANSFORMATION; BONE DISEASE; BONE MASS; BONE REMODELING; CELL DIFFERENTIATION; CELL PROLIFERATION; DNA DAMAGE; GENETICS; HUMAN; MESENCHYMAL STEM CELL; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRESS; TUMOR;

ANIMALS; BONE REMODELING; CELL DIFFERENTIATION; CELL PROLIFERATION; MICE; OSTEOBLASTS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78651299382     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22749     Document Type: Article

References (55)

1. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR, Altieri DC, Pratap J, Keller E, Stein GS, Lian JB. 2010. Runx2 association with progression of prostate cancer in patients: Mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 29:811-821.
2. Altieri DC, Languino LR, Lian JB, Stein JL, Leav I, vanWijnen AJ, Jiang Z, Stein GS. 2009. Prostate cancer regulatory networks. J Cell Biochem 107:845-852.
3. Boyle WJ, Simonet WS, Lacey DL. 2003. Osteoclast differentiation and activation. Nature 423:337-342.
4. Cao Y, Zhou Z, de Crombrugghe B, Nakashima K, Guan H, Duan X, Jia SF, Kleinerman ES. 2005. Osterix, a transcription factor for osteoblast differentiation, mediates antitumor activity in murine osteosarcoma. Cancer Res 65:1124-1128.
5. Celil AB, Campbell PG. 2005. BMP-2 and insulin-like growth factor-I mediate Osterix (Osx) expression in human mesenchymal stem cells via the MAPK and protein kinase D signaling pathways. J Biol Chem 280:31353-31359.
6. Chau JF, Leong WF, Li B. 2009. Signaling pathways governing osteoblast proliferation, differentiation and function. Histol Histopathol 24:1593-1606.
7. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Jr., Butel JS, Bradley A. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221.
8. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. 1997. Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation. Cell 89:747-754.
9. Gottlieb E, Haffner R, King A, Asher G, Gruss P, Lonai P, Oren M. 1997. Transgenic mouse model for studying the transcriptional activity of the p53 protein: Age- and tissue-dependent changes in radiation-induced activation during embryogenesis. EMBO J 16:1381-1390.
10. Harada S, Rodan GA. 2003. Control of osteoblast function and regulation of bone mass. Nature 423:349-355.
11. Harvey M, McArthur MJ, Montgomery CA, Jr., Butel JS, Bradley A, Donehower LA. 1993. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet 5:225-229.
12. Ho J, Benchimol S. 2003. Transcriptional repression mediated by the p53 tumour suppressor. Cell Death Differ 10:404-408.
13. Hu W, Feng Z, Teresky AK, Levine AJ. 2007. p53 regulates maternal reproduction through LIF. Nature 450:721-724.
14. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA. 1994. Tumor spectrum analysis in p53-mutant mice. Curr Biol 4:1-7.
15. Jones SN, Sands AT, Hancock AR, Vogel H, Donehower LA, Linke SP, Wahl GM, Bradley A. 1996. The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2. Proc Natl Acad Sci USA 93:14106-14111.
16. Kastan MB, Bartek J. 2004. Cell-cycle checkpoints and cancer. Nature 432: 316-323.
17. Khosla S. 2001. Minireview: The OPG/RANKL/RANK system. Endocrinology 142:5050-5055.
18. Ko LJ, Prives C. 1996. p53: Puzzle and paradigm. Genes Dev 10:1054-1072.
19. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T. 1997. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89:755-764.
20. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G. 2004. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119:861-872.
21. Lee MH, Kwon TG, Park HS, Wozney JM, Ryoo HM. 2003. BMP-2-induced Osterix expression is mediated by Dlx5 but is independent of Runx2. Biochem Biophys Res Commun 309:689-694.
22. Lengner CJ, Steinman HA, Gagnon J, Smith TW, Henderson JE, Kream BE, Stein GS, Lian JB, Jones SN. 2006. Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J Cell Biol 172:909-921.
23. Li B. 2005. c-Abl in oxidative stress, aging and cancer. Cell Cycle 4:246-248.
24. Li B. 2008. Bone morphogenetic protein-Smad pathway as drug targets for osteoporosis and cancer therapy. Endocr Metab Immune Disord Drug Targets 8:208-219.
25. Li B, Boast S, de los Santos K, Schieren I, Quiroz M, Teitelbaum SL, Tondravi MM, Goff SP. 2000. Mice deficient in Abl are osteoporotic and have defects in osteoblast maturation. Nat Genet 24:304-308.
26. Li B, Wang X, Rasheed N, Hu Y, Boast S, Ishii T, Nakayama K, Nakayama KI, Goff SP. 2004. Distinct roles of c-Abl and Atm in oxidative stress response are mediated by protein kinase C delta. Genes Dev 18:1824-1837.
27. Lian JB, Javed A, Zaidi SK, Lengner C, Montecino M, van Wijnen AJ, Stein JL, Stein GS. 2004. Regulatory controls for osteoblast growth and differentiation: Role of Runx/Cbfa/AML factors. Crit Rev Eukaryot Gene Expr 14:1-41.
28. Manolagas SC, Jilka RL. 1995. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332:305-311.
29. Martin TJ, Sims NA. 2005. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11:76-81.
30. Miller CW, Aslo A, Tsay C, Slamon D, Ishizaki K, Toguchida J, Yamamuro T, Lampkin B, Koeffler HP. 1990. Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res 50:7950-7954.
31. Molchadsky A, Shats I, Goldfinger N, Pevsner-Fischer M, Olson M, Rinon A, Tzahor E, Lozano G, Zipori D, Sarig R, Rotter V. 2008. p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PLoS One 3:e3707.
32. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, de Crombrugghe B. 2002. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108:17-29.
33. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. 2004. Mutant p53 gain of function in two mouse models of Li- Fraumeni syndrome. Cell 119:847-860.
34. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GW, Beddington RS, Mundlos S, Olsen BR, Selby PB, Owen MJ. 1997. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89:765-771.
35. Peterson CL, Cote J. 2004. Cellular machineries for chromosomal DNA repair. Genes Dev 18:602-616.
36. Porter DE, Holden ST, Steel CM, Cohen BB, Wallace MR, Reid R. 1992. A significant proportion of patients with osteosarcoma may belong to Li- Fraumeni cancer families. J Bone Joint Surg Br 74:883-886.
37. Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS, Lian JB. 2005. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 25:8581-8591.
38. Rasheed N, Wang X, Niu QT, Yeh J, Li B. 2006. Atm-deficient mice: An osteoporosis model with defective osteoblast differentiation and increased osteoclastogenesis. Hum Mol Genet 15:1938-1948.
39. Riggs BL, Khosla S, Melton LJ III. 2002. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23:279-302.
40. Rodan GA. 1992. Introduction to bone biology. Bone 13(Suppl 1): S3-S6.
41. Sakai A, Sakata T, Tanaka S, Okazaki R, Kunugita N, Norimura T, Nakamura T. 2002. Disruption of the p53 gene results in preserved trabecular bone mass and bone formation after mechanical unloading. J Bone Miner Res 17:119-127.
42. Sherr CJ. 1998. Tumor surveillance via the ARF-p53 pathway. Genes Dev 12:2984-2991.
43. Stein GS, Lian JB, van Wijnen AJ, Stein JL, Montecino M, Javed A, Zaidi SK, Young DW, Choi JY, Pockwinse SM. 2004. Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression. Oncogene 23:4315-4329.
44. Stiewe T. 2007. The p53 family in differentiation and tumorigenesis. Nat Rev Cancer 7:165-168.
45. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. 1999. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345-357. (Pubitemid 30649812)
46. Tataria M, Quarto N, Longaker MT, Sylvester KG. 2006. Absence of the p53 tumor suppressor gene promotes osteogenesis in mesenchymal stem cells. J Pediatr Surg 41:624-632.
47. Teitelbaum SL, Ross FP. 2003. Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638-649.
48. van der Deen M, Akech J, Wang T, FitzGerald TJ, Altieri DC, Languino LR, Lian JB, van Wijnen AJ, Stein JL, Stein GS. 2010. The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGFbeta in prostate cancer cells. J Cell Biochem 109:828-837.
49. Vogelstein B, Lane D, Levine AJ. 2000. Surfing the p53 network. Nature 408:307-310.
50. Wang X, Kua HY, Hu Y, Guo K, Zeng Q, Wu Q, Ng HH, Karsenty G, de Crombrugghe B, Yeh J, Li B. 2006. p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling. J Cell Biol 172:115-125.
51. Wang X, Goh CH, Li B. 2007. p38 mitogen-activated protein kinase regulates osteoblast differentiation through osterix. Endocrinology 148:1629-1637.
52. Yang X, Karsenty G. 2002. Transcription factors in bone: Developmental and pathological aspects. Trends Mol Med 8:340-345.
53. Zaidi SK, Pande S, Pratap J, Gaur T, Grigoriu S, Ali SA, Stein JL, Lian JB, van Wijnen AJ, Stein GS. 2007. Runx2 deficiency and defective subnuclear targeting bypass senescence to promote immortalization and tumorigenic potential. Proc Natl Acad Sci USA 104:19861-19866.
54. Zhou BB, Elledge SJ. 2000. The DNA damage response: Putting checkpoints in perspective. Nature 408:433-439.
55. Zhou Z, Flesken-Nikitin A, Corney DC, Wang W, Goodrich DW, Roy-Burman P, Nikitin AY. 2006. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res 66:7889-7898.